Recently, the FDA approved Vijoice (alpelisib) as a new dosage form of oral granules. Vijoice is the first FDA-approved treatment for patients with PROS. PROS are a group of genetic disorders in which mutations occur in the PIK3CA gene, causing overgrowth of certain body parts. Vijoice treats the condition by inhibiting the PI3K/Akt signalling pathway.